Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Sep 6. doi: 10.1001/jamaoncol.2018.3676. [Epub ahead of print]

PMID:
30193240
2.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.

PMID:
30120041
3.

Reply to: "Mortality due to immunotherapy related hepatitis".

De Martin E, Michot JM, Papouin B, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Oct;69(4):978-979. doi: 10.1016/j.jhep.2018.07.009. Epub 2018 Aug 7. No abstract available.

PMID:
30097327
4.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.

PMID:
30071444
5.

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.

Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL, Danlos FX, Dakdouki YE, Annereau M, Mariette X, Robert C, Cherif K, Marabelle A, Mateus C, Lambotte O.

Ann Rheum Dis. 2018 Jun 1. pii: annrheumdis-2018-213677. doi: 10.1136/annrheumdis-2018-213677. [Epub ahead of print] No abstract available.

PMID:
29858173
6.

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

De Martin E, Michot JM, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Aug;69(2):550-551. doi: 10.1016/j.jhep.2018.04.019. No abstract available.

PMID:
29776713
7.

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.

Eur J Cancer. 2018 Jun;96:91-104. doi: 10.1016/j.ejca.2018.03.006. Epub 2018 Apr 23.

PMID:
29698933
8.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.

PMID:
29427729
9.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
10.

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

Louvel G, Bahleda R, Ammari S, Le Péchoux C, Levy A, Massard C, Le Pavec J, Champiat S, Deutsch E.

Eur Respir J. 2018 Jan 4;51(1). pii: 1701737. doi: 10.1183/13993003.01737-2017. Print 2018 Jan. No abstract available.

PMID:
29301923
11.

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O.

Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18. No abstract available.

PMID:
29269089
12.

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Sun R, Danlos FX, Ammari S, Louvel G, Dhermain F, Champiat S, Lambotte O, Deutsch E.

J Immunother Cancer. 2017 Dec 19;5(1):96. doi: 10.1186/s40425-017-0304-8.

13.

Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication.

Michot JM, Ragou P, Carbonnel F, Champiat S, Voisin AL, Mateus C, Lambotte O, Annereau M.

J Immunother. 2018 Feb/Mar;41(2):84-85. doi: 10.1097/CJI.0000000000000202.

PMID:
29252914
14.

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors.

Michot JM, Pruvost R, Mateus C, Champiat S, Voisin AL, Marabelle A, Lambotte O.

Ann Oncol. 2018 Feb 1;29(2):518-520. doi: 10.1093/annonc/mdx701. No abstract available.

PMID:
29088318
15.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.

Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F.

Ann Oncol. 2017 Nov 1;28(11):2860-2865. doi: 10.1093/annonc/mdx403.

PMID:
29045560
16.

[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].

Champiat S, Soria JC.

Med Sci (Paris). 2017 Jun-Jul;33(6-7):563-564. doi: 10.1051/medsci/20173306001. Epub 2017 Jul 19. French. No abstract available.

17.

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL.

Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Review.

PMID:
28846956
18.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.

PMID:
28826073
19.

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.

Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10.

PMID:
28646772
20.

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.

Bernard-Tessier A, Jeanville P, Champiat S, Lazarovici J, Voisin AL, Mateus C, Lambotte O, Annereau M, Michot JM.

Eur J Cancer. 2017 Aug;81:135-137. doi: 10.1016/j.ejca.2017.05.017. No abstract available.

PMID:
28624693
21.

Immune-related bone marrow failure following anti-PD1 therapy.

Michot JM, Vargaftig J, Leduc C, Quere G, Burroni B, Lazarovici J, Champiat S, Ribrag V, Lambotte O.

Eur J Cancer. 2017 Jul;80:1-4. doi: 10.1016/j.ejca.2017.04.004. Epub 2017 May 17. No abstract available.

PMID:
28527392
22.

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.

Pradere P, Michot JM, Champiat S, Danlos FX, Marabelle A, Lambotte O, Albiges L, Le Pavec J.

Eur J Cancer. 2017 Apr;75:308-309. doi: 10.1016/j.ejca.2016.12.027. Epub 2017 Mar 1. No abstract available.

PMID:
28259013
23.

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O.

Ann Rheum Dis. 2018 Mar;77(3):468-470. doi: 10.1136/annrheumdis-2016-210820. Epub 2017 Feb 27. No abstract available.

PMID:
28242618
24.

Myocarditis with Immune Checkpoint Blockade.

Ederhy S, Voisin A-L, Champiat S.

N Engl J Med. 2017 Jan 19;376(3):290-1. No abstract available.

PMID:
28102662
25.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C.

Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.

26.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S.

Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21.

PMID:
27451022
27.

The development of immunotherapy in older adults: New treatments, new toxicities?

Helissey C, Vicier C, Champiat S.

J Geriatr Oncol. 2016 Sep;7(5):325-33. doi: 10.1016/j.jgo.2016.05.007. Epub 2016 Jun 16. Review.

PMID:
27318796
28.

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C.

Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4. Review.

PMID:
27141885
29.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O.

Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Review.

PMID:
26765102
30.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A.

Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28. Review.

PMID:
26715621
31.

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, Tomasic G, Soria JC, Champiat S, Texier M, Lanoy E, Robert C.

JAMA Dermatol. 2016 Jan;152(1):45-51. doi: 10.1001/jamadermatol.2015.2707.

PMID:
26501224
32.

[Breaking immune tolerance in cancer].

Desbois M, Champiat S, Chaput N.

Bull Cancer. 2015 Jan;102(1):34-52. doi: 10.1016/j.bulcan.2014.12.002. Epub 2015 Jan 13. Review. French.

PMID:
25609492
33.

Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.

Helissey C, Champiat S, Soria JC.

Curr Opin Oncol. 2015 Mar;27(2):108-17. doi: 10.1097/CCO.0000000000000167. Review.

PMID:
25602683
34.

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC.

Oncoimmunology. 2014 Jan 1;3(1):e27817. Epub 2014 Jan 16.

35.

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.

Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC.

J Thorac Oncol. 2014 Feb;9(2):144-53. doi: 10.1097/JTO.0000000000000074. Review.

36.

[Immunotherapies and targeted therapies in medical oncology].

Rousseau B, Champiat S, Loirat D, Arrondeau J, Lemoine N, Soria JC.

Bull Cancer. 2014 Jan 1;101(1):31-9. doi: 10.1684/bdc.2013.1865. Review. French.

PMID:
24333964
37.

[Immune-checkpoints: the new anti-cancer immunotherapies].

Ileana E, Champiat S, Soria JC.

Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771. Review. French.

PMID:
23735730
38.

T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenberg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF.

J Virol. 2013 Jun;87(11):6073-80. doi: 10.1128/JVI.00579-12. Epub 2013 Mar 27.

39.

Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF.

PLoS One. 2012;7(6):e39311. doi: 10.1371/journal.pone.0039311. Epub 2012 Jun 29.

40.

Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses.

Garrison KE, Champiat S, York VA, Agrawal AT, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF.

Clin Vaccine Immunol. 2009 Sep;16(9):1369-71. doi: 10.1128/CVI.00410-08. Epub 2009 Jul 1.

Supplemental Content

Loading ...
Support Center